Juridical Foundation the Chemo-sero-therapeutic Research Institute

Kagoshima University

Japan Science and Technology Agency

Judicial Foundation the Chemo-sero-therapeutic Res.

Kazuhisa Sugimura

Toshihiro Nakashima

Kenji Nakanishi

Masaharu Torikai

Tsukasa Nishihara

Kazuyuki Yoshizaki

Takumi Sasaki

Tsukasa; Nishihara

Toshihiro; Nakashima

The present invention provides a peptide which functions as a mimic peptide of an amyloid &#x3b2; peptide and is capable of inhibiting the fibrillogenesis of an amyloid &#x3b2; peptide. The present invention relates to an 8- to 30-amino acid residue peptide comprising an amino acid sequence represented by the following formula (I): X-Asp-X-X-X-Pro-X-X(SEQ ID NO: 28) (I), wherein Xrepresents a branched chain amino acid, and X, X, X, X, and Xare the same or different and each represents an &#x3b1;-amino acid, and to a pharmaceutical composition and an amyloid &#x3b2; fibrillogenesis inhibitor comprising the peptide.

Amyloid &#x3b2; fibrillogenesis-inhibiting peptide

This invention is intended to discover a peptide that induces production of an antibody specific for an abnormal amyloid &#x3b2; peptide from mimic peptides of the amyloid &#x3b2; peptide and to utilize the same as a vaccine or immunogen. This invention relates to a pharmaceutical composition containing a peptide consisting of 8 to 30 amino acid residues, wherein the peptide comprises at least one of an amino acid sequence represented by formula (I): Tyr-Gly-Thr-Lys-Pro-Trp-Met (SEQ ID NO: 28) (I), and an amino acid sequence represented by formula (II): Leu-Asp-Ile-Phe-Ala-Pro-Ile (SEQ ID NO: 29) (II); or a conjugate of such peptide and a carrier.

Peptide vaccine using mimic molecules of amyloid &#x3b2; peptide

A human anti-amyloid &#x3b2; peptide (hereinafter referred to as 'A&#x3b2;') antibody that binds to A&#x3b2; to thereby inhibit aggregation of A&#x3b2; molecules, and a fragment of said antibody are provided. The antibody and a fragment thereof according to the present invention, comprising a variable region of a human-derived anti-A&#x3b2; antibody, strongly reacts with A&#x3b2; to thereby inhibit its aggregation and hence may be used as a medicament for the prophylaxis and treatment of Alzheimer dementia.

Human anti-amyloid beta peptide antibody and fragment of said antibody

The present invention provides a peptide which functions as a mimic peptide of an amyloid &#x3b2; peptide and is capable of inhibiting the fibrillogenesis of an amyloid &#x3b2; peptide. The present invention relates to: an 8- to 30-amino acid residue peptide comprising an amino acid sequence represented by the following formula (I):X-Asp-X-X-X-Pro-X-X(SEQ ID NO: 28)&#x2003;&#x2003;(I)wherein Xrepresents a branched chain amino acid, and X, X, X, X, and Xare the same or different and each represents an &#x3b1;-amino acid; a 9- to 30-amino acid residue peptide comprising an amino acid sequence represented by the following formula (III):Z-X-Gly-X-X-Pro-Trp-Met-Z(SEQ ID NO: 31)&#x2003;&#x2003;(III)wherein X, X, and Xare the same or different and each represents an &#x3b1;-amino acid, Zand Zare the same or different and each represents cysteine or serine, and when Zand Zrepresent cysteine, they may be crosslinked; and a pharmaceutical composition and an amyloid &#x3b2; fibrillogenesis inhibitor comprising the peptide.

Amyloid [&#x3b2;] Beta fibrillogenesis-inhibiting peptide

Human anti-amyloid &#x3b2; peptide antibody and fragment of said antibody

A human-derived human anti-human IL-18 antibody of the present invention is an antibody against human IL-18, the antibody including: an H-chain complementarity determining region consisting of (a) a polypeptide consisting of amino-acid sequences represented by SEQ ID NOS: 4 to 6, or (b) a polypeptide which is a mutant of the polypeptide (a) and which serves as the H-chain complementarity determining region; and an L-chain complementarity determining region against human interleukin-18 consisting of (c) a polypeptide consisting of amino-acid sequences represented by SEQ ID NOS: 10 to 12, or (d) a polypeptide which is a mutant of the polypeptide (c) and which serves as the L-chain complementarity determining region. This makes it possible to provide a human anti-human IL-18 antibody and a method for using the antibody.

Human anti-human interleukin-18 antibody, fragment thereof and method for using same

A substance effective for treating immunopathy where interleukin 6 (IL-6) is involved is provided. A human anti-human IL-6 antibody and a human anti-human IL-6 antibody fragment having a high affinity to human IL-6 were obtained using phage antibody technique. The antibody and antibody fragment are expected to be useful as a medicament for treating inflammation and immunopathy caused by IL-6.

Human antihuman interleukin-6 antibody and fragment of antibody

An antibody or an antibody fragment is provided that is efficacious for treating allergic diseases in which IgE is involved. A human antibody and a fragment thereof to a receptor (Fc&#x3b5;RI) having high affinity to Fc portion of IgE was obtained using phage antibody display technique. The human anti-IgE receptor antibody and a fragment thereof of the invention has an activity to inhibit the binding between IgE and IgE receptor and hence is expected to be useful as a medicament for treating allergic diseases caused by the binding between IgE and IgE receptor.

Human type antihuman IgE receptor antibody and fragment

A substance effective for treating immunopathy where MCP-1 is involved is provided. scFv having a high affinity to human MCP-1 was obtained using phage antibody technique. Based on information of VH chain and VL chain obtained from said scFv, a human anti-human MCP-1 antibody and a human anti-human MCP-1 antibody fragment are obtained. Said antibody and antibody fragment are expected to be useful as a medicament for treating inflammation and immunopathy caused by MCP-1.

Human antihuman MCP-1 antibody and antibody fragment thereof

An immunoregulatory molecule that regulates costimulatory signal transduction through interaction with the molecules involved in costimulatory signal transduction present on antigen presenting cells and/or T cells in the activation of T cells by antigen presenting cells and a process for preparing the same are provided. Said immunoregulatory molecule comprises a peptide which has two cysteine (Cys) residues forming Cys-Cys linkage and comprises at least six amino acid residues between said Cys-Cys linkage. Said immunoregulatory molecule is obtained by screening a phage random peptide library with a monoclonal antibody to CTLA-4 on T cells involved in costimulatory signal transduction.

Growing community of inventors

Kagoshima, Japan

Kazuhisa Sugimura